FULL PAPERS
Atmospheric Pressure of CO2 as Protecting Reagent and Reactant
128.3, 128.1, 126.4, 125.1, 120.9, 111.3, 102.6, 55.6, 41.4, 29.0,
19.7, 13.5; HR-MS (ESI): m/z=360.1593, calcd. for
C21H23NO3Na [M+Na]+: 360.1570; EI-MS: m/z (%)=
210.10 (100), 337.20 (47) [M+].
Typical Procedure for the Synthesis of Oxazolidin-2-
ones
To a 10-mL reaction tube, the copper catalyst (5 mol%), sol-
vent (0.4 mL), alkyne (2 mmol), aldehyde (2 mmol), and car-
bamate salt (1 mmol) were added. The reactions were car-
ried out in screw cap vials with a Teflon seal at 808C for
18 h. The reaction mixture was allowed to cool to room tem-
perature and the crude reaction mixture was further purified
by column chromatography (silica gel, petroleum ether/
EtOAc) to afford the desired product oxazolidinones.
(Z)-5-Benzylidene-3-butyl-4-(4-chlorophenyl)oxazolidin-
2-one (5f): 1H NMR (CDCl3, 400 MHz): d=7.55–7.50 (m,
2H), 7.40–7.38 (m, 2H), 7.33–7.25 (m, 4H), 7.20–7.16 (m,
1H), 5.35 (s, 1H), 5.22 (s, 1H), 3.51–3.47 (m, 1H), 2.82–2.79
(m, 1H), 1.46–1.40 (m, 2H), 1.29–1.26 (m, 2H), 0.88 (t, 3H,
J=7.6 Hz); 13C NMR (CDCl3, 100.6 MHz): d=154.7, 147.1,
135.8, 135.2, 133.1, 131.6, 129.4, 129.0, 128.2, 126.9, 104.7,
63.0, 41.5, 28.8, 19.6, 13.5; HR-MS (ESI): m/z=364.1095,
calcd. for C20H20ClNO2Na [M+Na]+: 364.1075; EI-MS: m/z
(%)=214.10 (100), 341.20 (36) [M+].
(Z)-5-Benzylidene-3-butyl-4-(2-chlorophenyl)oxazolidin-
2-one (5g): 1H NMR (CDCl3, 400 MHz): d=7.78–7.76 (m,
1H), 7.51–7.25 (m, 8H), 5.25 (s, 1H), 5.07 (s, 1H), 3.37–3.33
(m, 1H), 2.63–2.61 (m, 1H), 1.44–1.40 (m, 2H), 1.29–1.26
(m, 2H), 0.89 (t, 3H, J=7.8 Hz); 13C NMR (CDCl3,
100.6 MHz): d=155.03, 146.28, 137.87, 133.16, 131.64,
129.67, 129.21, 128.92, 128.34, 128.29, 127.03, 122.92, 104.06,
51.74, 41.65, 31.90, 19.71, 13.52; HR-MS (ESI): m/z=
364.1104, calcd. for C20H20ClNO2Na [M+Na]+: 364.1075;
EI-MS: m/z (%)=179.10 (100), 341.10 (43) [M+].
Characterization Data of Oxazolidin-2-ones
(Z)-5-Benzylidene-3-butyl-4-phenyloxazolidin-2-one
(5a):
1H NMR (CDCl3, 400 MHz): d=7.53–7.51 (m, 2H), 7.44–
7.42 (m, 3H), 7.35–7.28 (m, 4H), 7.20–7.17 (m, 1H), 5.38 (d,
1H, J=2.0 Hz), 5.25 (d, 1H, J=2.0 Hz), 3.55–3.48 (m, 1H,),
2.86–2.80 (m, 1H), 1.46–1.44 (m, 2H), 1.29–1.25 (m, 2H),
0.88 (t, 3H, J=7.4 Hz); 13C NMR (CDCl3, 100.6 MHz): d=
155.1, 147.7, 137.3, 133.5, 129.4, 129.3, 128.4, 128.3, 127.8,
126.9, 104.5, 63.9, 41.6, 29.0, 19.8, 13.6; HR-MS (ESI): m/z=
330.1471, calcd. for C20H21NO2Na [M+Na]+: 330.1465; EI-
MS: m/z (%)=180.10 (100), 307.20 (41) [M+].
(Z)-5-Benzylidene-3-butyl-4-(p-tolyl)oxazolidin-2-one
(Z)-5-Benzylidene-3-butyl-4-(4-hydroxyphenyl)oxazolidin-
2-one (5h): 1H NMR (CDCl3, 400 MHz): d=9.84 (s, 1H),
7.81–7.79 (m, 2H), 7.50–7.48 (m, 2H), 7.29–7.20 (m, 2H),
7.18–7.17 (m, 3H), 5.36 (s, 1H), 5.27 (s, 1H), 3.49–3.44 (m,
1H), 2.85–2.81 (m, 1H), 1.29–1.27 (m, 2H), 1.26–1.25 (m,
2H), 0.87 (t, 3H, J=7.4 Hz); 13C NMR (CDCl3, 100.6 MHz):
d=156.9, 155.5, 147.8, 132.5, 129.4, 128.4, 128.3, 127.0, 116.1,
116.2, 104.7, 63.5, 41.5, 28.9, 19.7, 13.6; HR-MS (ESI): m/z=
346.1433, calcd. for C20H21NO3Na [M+Na]+: 346.1414; EI-
MS: m/z (%)=196.10 (100), 323.20 (21) [M+].
(Z)-4-(5-Benzylidene-3-butyl-2-oxooxazolidin-4-yl)-benzo-
nitrile (5i): 1H NMR (CDCl3, 400 MHz): d=7.78–7.77 (m,
2H), 7.48–7.45 (m, 4H), 7.29–7.24 (m, 2H), 7.18–7.16 (m,
1H), 5.43 (s, 1H), 5.20 (s, 1H), 3.54–3.52 (m, 1H), 2.80–2.81
(m, 1H), 1.46–1.40 (m, 2H), 1.29–1.26 (m, 2H), 0.87 (t, 3H,
J=7.4 Hz); 13C NMR (CDCl3, 100.6 MHz): d=154.9, 146.1,
142.4, 133.5, 132.4, 128.4, 128.3, 128.3, 127.0, 117.7, 113.2,
104.7, 63.5, 41.5, 28.9, 19.7, 13.6; HR-MS (ESI): m/z=
355.1426, calcd. for C21H21NO2Na [M+Na]+: 355.1418; EI-
MS: m/z (%)=205.10 (100), 332.20 (56) [M+].
(5b): 1H NMR (CDCl3, 400 MHz): d=7.50–7.48 (m, 2H),
7.24–7.11 (m, 7H), 5.29 (s, 1H), 5.21 (s, 1H), 3.47–3.44 (m,
1H), 2.81–2.77 (m, 1H), 2.33 (s, 3H), 1.43–1.38 (m, 2H),
1.28–1.21 (m, 2H), 0.87 (t, 3H, J=7.6 Hz); 13C NMR
(CDCl3, 100.6 MHz): d=154.7, 147.8, 139.0, 134.0, 133.3,
129.7, 128.1, 128.0, 127.5, 126.5, 104.0, 63.3, 41.2, 28.6, 20.9,
19.5, 13.3; HR-MS (ESI): m/z=344.1636, calcd. for
C21H23NO2Na [M+Na]+: 344.1621; EI-MS: m/z (%)=
194.10 (100), 321.20 (34) [M+].
(Z)-5-Benzylidene-3-butyl-4-(4-methoxyphenyl)oxazoli-
din-2-one (5c): 1H NMR (CDCl3, 400 MHz): d=7.52–7.50
(m, 2H), 7.30–7.28 (m, 3H), 7.23–7.18 (m, 1H), 7.17–7.15
(m, 1H), 6.94–6.92 (m, 2H), 5.34 (d, 1H, J=2.0), 5.24 (d,
1H, J=2.0), 3.81 (s, 1H), 3.48–3.43 (m, 1H), 2.83–2.79 (m,
1H), 1.46–1.42 (m, 2H), 1.29–1.25 (m, 2H), 0.87 (t, 3H, J=
7.8 Hz); 13C NMR (CDCl3, 100.6 MHz): d=160.2, 154.8,
148.0, 133.4, 129.1, 129.0, 128.3, 128.2, 126.7, 114.5, 104.2,
63.3, 55.2, 41.4, 28.8, 19.7, 13.5; HR-MS (ESI): m/z=
360.1595, calcd. for C21H23NO3Na [M+Na]+: 360.1570; EI-
MS: m/z (%)=210.10 (100), 337.20 (18) [M+].
(Z)-5-Benzylidene-3-cyclopentyl-4-phenyloxazolidin-2-one
(5j): 1H NMR (CDCl3, 400 MHz): d=7.59–7.57 (m, 1H),
7.48–7.35 (m, 2H), 7.29–7.24 (m, 6H), 7.18–7.16 (m, 1H),
5.38 (s, 1H), 5.17 (s, 1H), 3.83–3.79 (m, 1H), 1.90–1.88 (m,
2H), 1.76–1.71 (m, 2H), 1.47–1.43 (m, 4H); 13C NMR
(CDCl3, 100.6 MHz): d=154.5, 148.0, 139.1, 133.5, 131.6,
129.1, 128.3, 128.2, 127.5, 126.7, 104.1, 64.2, 55.9, 29.6, 24.1;
HR-MS (ESI): m/z=342.1482, calcd. for C21H21NO2Na [M+
Na]+: 342.1465; EI-MS: m/z (%)=180.10 (100), 319.10 (42)
[M+].
(Z)-5-Benzylidene-3-cyclohexyl-4-phenyloxazolidin-2-one
(5k): 1H NMR (CDCl3, 400 MHz): d=7.56–7.54 (m, 2H),
7.42–7.39 (m, 3H), 7.36–7.31 (m, 5H), 7.22–7.19 (m, 1H),
5.43 (s, 1H), 5.20 (s, 1H), 3.61–3.55 (m, 1H), 1.82–1.75 (m,
3H), 1.71–1.66 (m, 3H), 1.36–1.23 (m, 5H); 13C NMR
(CDCl3, 100.6 MHz): d=154.5, 148.2, 139.4, 133.4, 131.6,
129.0, 128.4, 128.1, 127.6, 126.6, 104.0, 63.0, 54.5, 31.0, 25.5,
24.9; HR-MS (ESI): m/z=356.1642, calcd. for C22H23NO2Na
(Z)-5-Benzylidene-3-butyl-4-(3-methoxyphenyl)oxazoli-
din-2-one (5d): 1H NMR (CDCl3, 400 MHz): d=7.53–7.51
(m, 2H), 7.36–7.26 (m, 3H), 7.20–7.18 (m, 1H), 6.95–6.91
(m, 2H), 6.84–6.83 (m, 1H), 5.35 (d, 1H, J=2.0), 5.28 (d,
1H, J=2.0), 3.82 (s, 3H), 3.55–3.51 (m, 1H), 2.86–2.82 (m,
1H), 1.49–1.45 (m, 2H), 1.33–1.26 (m, 2H), 0.89 (t, 3H, J=
7.8 Hz); 13C NMR (CDCl3, 100.6 MHz): d=160.3, 155.0,
147.4, 138.8, 133.4, 130.3, 128.4, 128.3, 126.9, 120.0, 114.6,
113.1, 104.4, 63.7, 55.3, 41.6, 28.9, 19.8, 13.6; HR-MS (ESI):
m/z=360.1595, calcd. for C21H23NO3Na f[M+Na]+:
360.1570; EI-MS: m/z (%)=210.10 (100), 337.20 (18) [M+].
(Z)-5-Benzylidene-3-butyl-4-(2-methoxyphenyl)oxazoli-
din-2-one (5e): 1H NMR (CDCl3, 400 MHz): d=7.54–7.52
(m, 2H), 7.38–7.34 (m, 1H), 7.29–7.22 (m, 3H), 7.17–7.14
(m, 1H), 7.00–6.93 (m, 2H), 5.71 (s, 1H), 5.31 (s, 1H), 3.84
(s, 1H), 3.54–3.46 (m, 1H), 2.77–2.73 (m, 1H), 1.46–1.45 (m,
2H), 1.30–1.26 (m, 2H), 0.87 (t, 3H, J=7.8 Hz); 13C NMR
(CDCl3, 100.6 MHz): d=157.8, 155.4, 147.6, 133.8, 130.4,
Adv. Synth. Catal. 2016, 358, 90 – 97
ꢀ 2016 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
95